Generic name: diatrizoate meglumine and diatrizoate sodium
Dosage form: Injection, USP 76%
This dosage information does not include all the information needed to use Hypaque-76 safely and effectively. See full prescribing information for Hypaque-76.
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
Preparation of the patient will vary with preference of the radiologist and the type of radiological procedure performed. Specific radiographic procedures used will depend on the state of the patient and the diagnostic indications. Individual dose should be tailored according to age, body size, and indication for examination. (See INDIVIDUAL INDICATIONS AND USAGE section for specific Dosage and Administration.)
Solutions of radiopaque diagnostic agents for intravascular use should be at body temperature when injected and may need to be warmed before use. In the event that crystallization occurs, the solution may be clarified by placing the vial in a water bath at 40°C to 50°C and shaking it gently for two to three minutes or until the solids redissolve. If the particles still persist, do not use this vial but discard it. The solution may be autoclaved once.
The solution should be stored at room temperature and protected from strong light and any unused portion remaining in the container should be discarded.
Dilution and withdrawal of the contrast agents should be accomplished under aseptic conditions with sterile syringes.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Avoid contaminating catheters, syringes, needles, and contrast media with glove powder or cotton fibers.
Pediatric doses of injectable radiopaque diagnostic agents are generally determined on a weight basis and should be calculated for each patient individually. (See INDIVIDUAL INDICATIONS AND USAGE section.)
Diatrizoate salts are incompatible in vitro with some antihistamines and many other drugs. It is believed that one of the chief causes of in vitro incompatibility is an alteration of pH. Turbidity of solutions of intravascular contrast medium occurs between pH 2.5 and 4.1. Another cause is chemical interaction; therefore, other pharmaceuticals should not be mixed with contrast agents in the same syringe.
- Hypaque-76 Drug Interactions
- Cystografin (diatrizoate meglumine) Injection dosage information
- Gastrografin (diatrizoate meglumine and diatrizoate sodium) oral, rectal liquid dosage information
- Hypaque (diatrizoate sodium) Oral Powder dosage information
- Reno-30 (diatrizoate meglumine) injection dosage information
- Reno-60 (diatrizoate meglumine) injection dosage information
- Reno-Dip (diatrizoate meglumine) Injection dosage information
- RenoCal-76 (diatrizoate meglumine and diatrizoate dodium) Injection USP dosage information
- Renografin-60 (diatrizoate meglumine and diatrizoate sodium) Injection dosage information